Clinical Trials
23 trialsNCT02710734 2026-05-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Completed
NCT03348969 2026-03-03
NICSA
Aarhus University Hospital
Phase 4 Completed
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT03658304 2024-11-05
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
Phase 2 Completed
NCT00981656 2024-09-19
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT00318643 2021-10-29
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02793128 2020-12-22
Olympus
UroGen Pharma Ltd.
Phase 3 Completed
NCT03694535 2018-10-03
Intravesical Thermochemotherapy With Mitomycin-c
TC Erciyes University
Phase NA Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT02311101 2015-12-03
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT00734994 2015-06-29
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT00002490 2013-12-18
Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00024349 2013-12-18
Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01920269 2013-08-09
EMDA/MMC
University of Rome Tor Vergata
Phase 2/3 Completed
NCT00023842 2012-09-24
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01149174 2011-10-04
EMDA/PRE-TUR
University of Rome Tor Vergata
Phase 3 Completed
NCT01442519 2011-09-28
BCG/EMDA-MMC
University of Rome Tor Vergata
Phase 3 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed